Drug intelligence / Profile preview

NOVS-104

Development stage: Preclinical
Lead developer: Celloram
Modality: Small Molecules
Administration: Oral

Overview

NOVS-104 is a preclinical-stage small molecule inhibitor developed by Celloram. It is designed to target Fatty Acid Binding Protein 4 (FABP4) and Fatty Acid Binding Protein 5 (FABP5), which are key mediators in lipid transport and inflammatory signaling pathways. By inhibiting these proteins, NOVS-104 aims to address the underlying pathophysiology of metabolic diseases, specifically obesity and type 2 diabetes (T2D). The therapeutic rationale involves modulating fatty acid metabolism to improve insulin sensitivity and reduce chronic inflammation associated with adipose tissue dysfunction.

Targets

FABP5 (Fatty acid-binding protein 5)FABP4 (Fatty acid-binding protein 4)

Beyond the preview

Go deeper on NOVS-104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NOVS-104.

Explore the full profile